The trial is a 300-patient, randomized placebo-controlled study at 18 sites in the U.S. and two sites in Israel. The primary endpoint is a statistically significant improvement in ADHD symptoms versus placebo as measured by the Conners' Adult ADHD Rating Scale.
Patient enrollment complete in Metadoxine Phase 3
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs